Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. Details of the molecular mechanisms involved in the pathogenesis of this leukemia are unclear at present. In other malignancies tumorigenesis has been shown to proceed via a multistep progression model with a causal relation between the accumulation of genetic abnormalities and more aggressive clinical behavior. The loss of chromosomal segments in malignant cells has proven useful in mapping regions of DNA that contain candidate tumor suppressor genes. The detection of loss of heterozygosity (LOH) has been greatly facilitated by the analysis of highly polymorphic microsatellite markers enabling the identi®cation of submicroscopic losses. Utilizing immunomagnetic bead sorting to separate leukemic from normal cells we identi®ed at least one allelic losses in 8/29 (28%) of analysed CLL cases with a PCR-based assay. On chromosomal arm 3p we have identi®ed homozygous deletions in 3/29 cases at locus D3S1284 residing in the vicinity of the newly described FHIT gene. Several cases of CLL manifested LOH at a locus telomeric to the p15 and p16 tumor suppressor genes, all being early to intermediate stage disease. Our ®ndings suggest that losses at these loci may contribute to the development and/or progression of CLL in at least a subset of cases.
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Keywords: allelic losses; chronic lymphocytic leukemia; microsatellite markers Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. While CLL in its early stages often manifests few or no symptoms, the leukemia almost invariably progresses requiring some form of therapy. Despite recent innovative therapies including the use of purine analogoues, CLL is an incurable disease at present (O'Brien et al., 1995) . Details of the molecular mechanisms involved in the pathogenesis of this leukemia are unclear at present. Two major chromosomal abnormalities, trisomy 12 and deletions of 13q14 have been identi®ed in a minority of cases, however few details concerning the speci®c genetic perturbations involved in the initiation and progression of this malignancy are known (Juliusson et al., 1988; Juliusson et al., 1990) . There are no consistent overexpression or constitutive activation of known oncogenes in CLL (Raghobier et al., 1991) . The Bcl-2 gene, translocated t(14;18) in a majority of low grade lymphomas, is rearranged in CLL in only a minority of cases (Schena et al., 1992) .
Another potential mechanism for malignant transformation is the inactivation of tumor suppressor genes. The characterization of candidate tumor suppressor genes involved in the pathogenesis of this common adult leukemia are still limited. Loss of both alleles or loss of heterozygosity (LOH) with mutations in the remaining allele is a common mechanism for inactivating tumor suppressor genes. Allelic losses and point mutations involving the p53 tumor suppressor gene, have been identi®ed in 15 ± 20% of CLL cases analysed (Gaidano et al., 1991; Fenaux et al., 1992) . In two common solid tumors, colorectal cancer and more recently head and neck cancer, tumorigenesis has been shown to proceed via a multistep genetic progression model with a causal relation between the accumulation of genetic abnormalities and more aggressive clinical behaviour (Fearon et al., 1990; Califano et al., 1996) . CLL is a leukemia with distinct clinical stages strati®ed according to the RAI or Binet classi®cation, correlating extent of tumor burden with stage in early disease and degree of marrow involvement with stage as the leukemia progresses (Rai et al., 1975; Binet et al., 1977) . CLL is therefore an ideal malignancy in which to study patterns and frequency of allelic loss as the leukemia progresses. The deletion of chromosomal segments in malignant cells has previously proven useful in mapping regions of DNA that contain candidate tumor suppressor genes (Stanbridge et al., 1990; Boring et al., 1994) . While previous studies have examined the role of sequential karyotypic alterations in the progression of CLL, the ®ndings to date do not support karyotypic evolution as a frequent occurrence in this leukemia (Hannam-Harris et al., 1984; Nowell et al., 1988) . However, this type of analysis will not detect submicroscopic deletions. The detection of LOH has been greatly facilitated by the analysis of highly polymorphic microsatellite markers enabling the identi®cation of submicroscopic losses not detectable by karyotype analysis. Recent studies have demonstrated the utility of ampli®cation of microsatellite markers for analysis of allelic loss (Ruppert et al., 1993; Merlo et al., 1994) .
In a recent report we described the presence of microsatellite instability in a small subset of CLL (Gartenhaus et al., 1996a) . This work was made feasible by our ability to obtain highly puri®ed populations of neoplastic and normal cells by an immunomagnetic bead separation protocol. Using a PCR-based assay to detect microsatellite alterations in our tumor samples compared to matched normal samples we also observed several examples of allelic loss. The availability of highly puri®ed tumor and normal cell populations obtained from 29 CLL patients at dierent stages of diseases prompted us to examine these samples in greater detail for allelic losses. We screened all 29 cases with highly polymorphic microsatellite markers at 12 loci on nine dierent autosomal chromosomal arms using a PCR-based assay.
Puri®ed populations of B-cell CLL cells (CD5+, CD19+) and matched normal T-cells (CD3+, CD4+) were obtained as described in Figure 1 . The clinical characteristics of our 29 CLL cases have previously been described (Gartenhaus et al., 1996b) . Allelic loss was identi®ed from informative cases when the band pattern demonstrated clear LOH (reduction of band intensity by 450%) and were reproducible in replicate assays. Homozygous deletions (biallelic loss) were identi®ed when there was a reduction of band intensity by 490%. Markers and marker position were obtained from the Genethon human genetic linkage map (Gyapay et al., 1994) and the genome data base. One major caveat in analysing allelic losses, detected by using a PCR-based assay with microsatellite markers is the confounding impact on data interpretation by the presence of widespread microsatellite instability (mutator phenotype). This potential obstacle was not problematic in our identi®cation of allelic loss since we had previously examined all CLL cases analysed in this present study for this phenotype. In only one sample exhibiting any allelic losses (CLL 140), was there evidence of microsatellite instability. While a number of alleles were deleted in only one to two cases of examined CLL samples, this may represent background loss and therefore not have any clinical or biological signi®cance (Table 1) . For this reason we only analysed in detail those allelic losses, either heterozygous or homozygous observed in greater than 10% of evaluated cases.
LOH and deletions on the short arm of chromosome 3 have been implicated in dierent types of lung cancer (Ganly et al., 1992; Daly et al., 1993) . We have identi®ed three cases with homozygous deletions of the microsatellite marker D3S1285 whose chromosomal localization is 3p14.2-14.1 (Figure 2 ). This region has been shown recently to be the site of the newly described FHIT gene proposed as a candidate tumor suppressor gene in a variety of airway and digestive tract tumors (Ohta et al., 1996) . A recent report evaluating this gene in a panel of colorectal cancer cell lines calls into question its role in colon carcinoma (Thiagalingan et al., 1996) . There may be another target gene(s) located in this region involved in the formation of these common tumors. While the relevance of the FHIT gene to tumor development is unresolved at present, our data suggest the potential involvement of this region in some case of CLL. While the number of cases with this homozygous deletion were few in our study, it may be signi®cant that two to three were either stage 4 or a Richter's transformation. The role that losses at this region contribute to the progression of advanced disease awaits further analysis of larger numbers of cases with additional markers.
There was LOH at the microsatellite marker D9S747 in 5/29 (17%) cases (Figure 3) , with all ®ve of these being either stage 1 or 2 disease. This high rate of allelic loss at this microsatellite marker is of interest since losses on chromosomal band 9p21 are a common occurrence in other human tumors (Cairns et al., 1995) . Two groups have recently described homozygous deletions of the CDKN2 gene in some high-grade lymphomas (Otsuki et al., 1995; Seibert et al., 1995) , this gene residing on this chromosomal arm. However, since the marker D9S747 used in our Figure 1 Scheme for magnetic bead separation of CLL and normal T cells: A sequential magnetic bead separation protocol was devised to purify two populations of cells; a doubly positive CD5, CD19 cell (B-cell CLL phenotype) or a doubly positive CD3, CD4 (T-cell phenotype) referred to as tumor or normal cell, respectively. Thawed cells were washed then resuspended in 2 ml of`complete' RPMI 1640 media containing 10% fetal bovine serum, 50 mg/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml neomycin, and 2 mmol/l L-glutamine (GIBCO, Grand Island, NY). One-milliliter aliquots of cells were incubated with magnetic beads coated with either anti-CD5 or anti-CD3 antibodies (Perceptive Diagnostics, Inc, Cambridge, MA) at a bead/target cell ration of approx. 1 : 1. After a 30 min incubation on ice the magnetic bead coated cells were separated using a magnet and resuspended in 5 ml of fresh media. To permit the magnetic particles to fall away from the cells because of cell-surface turnover, an additional 30 to 40 h of incubation at 378C was performed. The cells were next pelleted and resuspended in 1 ml of media, with the detached beads separated by magnet. After transferring the cells to a new test tube, anti-CD19 or anti-CD4 coated beads (Perceptive Diagnosis, Inc, Cambridge, MA) were added to either CD5+ or CD3+ cells, respectively. An additional 30 min incubation on ice was performed and magnetic bead coated cells were isolated by magnet and used for subsequent DNA preparation. Flow-cytometry con®rmed the separation of two distinct cell populations. DNA extraction: The puri®ed doubly positive CD3+, CD4+ cells and CD5+, CD19+ cells were extracted for DNA using the Micro-Turbo Gen DNA isolation kit (Invitrogen, SanDiego, CA) Allelic losses in chronic lymphocytic leukemia RB Gartenhaus screen is telomeric to this region containing at least two putative tumor suppressor genes we may be underestimating the involvement of these gene(s) in the initiation or progression of CLL. Ongoing studies entailing analysis of markers¯anking these genes will help clarify whether a novel tumor suppressor locus is present or whether we simply detected an overlapping region that is lost together with these two genes. A number of investigators using dierent techniques have identi®ed putative tumor suppressor genes in lymphoproliferative malignancies. Several groups employing high resolution banding,¯uorescence in situ hybridization (FISH), and loss of heterozygosity analysis (LOH) have identi®ed a common region of deletion on the long arm of chromosome 6 in nonHodgkin's lymphoma (Menasce et al., 1994; Ot et al., 1994) . Chaganti et al. have described frequent deletions in regions 9p21-22 and 9q31-34 of diuse large cell lymphomas (Chaganti et al., 1995) . Two groups have described the homozygous deletion of the cyclin-dependent kinase 4 inhibitor (CDKN2) gene in lymphoid malignancies (Otsuki et al., 1995; Siebert et al., 1995) . These prior studies did not include a large panel of CLL cases. The two aected loci reported in this work on chromosomal arms 3p and 9p have not been associated with CLL before to our knowledge. Recently, a novel tumor suppressor gene has been proposed to reside in the vicinity of the microsatellite marker D13S319 as determined by loss of heterozygosity (LOH) analysis in some cases of CLL (Liu et al., 1995) . In correlating the clinico-pathologic characteristics of CLL cases that manifested these allelic losses we made several observations (Table 2 ). All cases that exhibited loss at locus D9S747 were either early to intermediate disease. One case CLL (11), a stage 1 disease had losses at both loci. This association of allelic losses involving these two speci®c loci suggests that in at least a subset of CLL there are non-random genetic alterations involved in the initiation and/or progression of this common adult leukemia. In further support of our ®ndings having biological relevance is the fact that the two involved loci are in close proximity to regions containing previously identi®ed putative tumor suppressor genes. We believe that these ®ndings warrant screening a large number of cases of CLL at all stages Three samples; CLL 7, CLL 11, and CLL 32 showed loss of both alleles using marker D3S1285. Pcr-based microsatellite marker analysis was performed as previously described (Gartenhaus et al., 1996a) . Brie¯y, 1 microliter of either normal or tumor DNA (appx. 50 ng) was used as PCR template in a 50 ml reaction mixture. One primer of each respective primer pair for every microsatellite locus analysed was end-labeled with [ 32 P] adenosine triphosphate (New England Nuclear) using the 5' DNA Terminus Labeling System according to the supplier's instructions (Gibco, Grand Island, NY) . Both tumor and normal DNA were subjected to 30 cycles of PCR with automated temperature cycling program as below: step-cycle ®le for 30 cycles: 948C61 min; 608C62 min, and 728C63 min; time-delay ®le: 728C67 min and soak ®le, 48C PCR products were run on denaturing 8 mol/l urea polyacrylamide gels run at 70 W for 90 min with autoradiography performed for 2 ± 12 h. After autoradiography was performed densitometric analysis was carried out to score for allelic loss. Homozygous deletion was scored if the signal intensity of the targeted allele was 490% reduced in comparison to the control allele. The DCC locus was simultaneously ampli®ed in these samples with no LOH observed con®rming that our ®ndings were not due to PCR failure (data not shown). All allelic losses were reproducible in replicate assays 7  1 1  3 0  39  48  52  89  140  142  TN  TN  TN  TN  TN  TN  TN  TN of diseases for allelic losses at these two involved loci. The identi®cation of minimal regions of loss for these involved regions will enable investigators to determine if novel tumor suppressor genes are involved in the pathogenesis of CLL. Delineating the sequence of genetic losses as CLL clinically progresses will permit the development of a genetic progression model for CLL which may have important clinical rami®cations. The current clinicopathologic criteria employed in predicting clinical behaviour within a given stage are often not very helpful. Consequently, it is unclear which patients might bene®t from early therapeutic intervention. A potentially useful role for such a model would be to de®ne poor risk patients within a speci®c stage by their allelotype and to modify treatment for these individuals if a speci®c genetic alteration(s) is associated with rapid clinical progression or poor response to therapy. Such a strategy would spare good risk patients the potentially deleterious eects of chemotherapy. The p53 tumor supressor gene is involved in the cytotoxicity mediated by purine analog treatment of CLL cells in vitro (Gartenhaus et al., 1996b) and while mutated in only a minority of CLL cases has been shown to predict strongly for resistance to purine analog therapy in vivo (Dohner et al., 1995) . The presence of a wild-type p53 protein in our CLL samples (manuscript in preparation) further supports the likelihood of inactivation of other tumor suppressor genes for the initiation/progression of this common leukemia. Furthermore, identi®cation of these putative tumor suppressor genes may ultimately reveal the underlying genetic mechanisms responsible for the often unpredictable behavior of CLL and identify potential targets for rational therapeutic intervention.
